DOI: 10.12890/2026_007266
Unmasking macrophage activation syndrome in VEXAS syndrome: a diagnostic challenge
Authors
aboissais@gmail.com
Keywords
VEXAS syndrome, macrophage activation syndrome, hemophagocytic lymphohistiocytosis, UBA1 mutation, autoinflammatory diseaseAbstract
Introduction: Vacuoles, E1 Enzyme, X-linked, Auto-inflammatory, Somatic (VEXAS) syndrome is a late-onset autoinflammatory disease caused by somatic mutations in the UBA1gene. Macrophage activation syndrome (MAS) is a rare but life-threatening hyperinflammatory condition whose association with VEXAS syndrome remains poorly described.
Case description: We report three cases of MAS occurring in men aged 65 to 72 years with genetically confirmed VEXAS syndrome. In all cases, MAS was characterized by fever, recent-onset cytopenias, marked hyperferritinaemia, and a high probability of MAS according to the H-score (>93%). Bone marrow examination demonstrated haemophagocytosis in two patients and numerous activated macrophages in one. Extensive investigations failed to identify infectious, malignant, or drug-related triggers. In one patient, MAS preceded the diagnosis of VEXAS syndrome by several years. In the two others, MAS occurred during the course of established VEXAS disease and was considered a manifestation of disease flare. Treatment included high-dose corticosteroids, with additional anakinra in one patient and etoposide in another, resulting in rapid clinical and biological improvement. One patient experienced MAS relapse following granulocyte colony-stimulating factor exposure during azacitidine treatment, whereas no recurrence was observed in the other two patients during follow-up.
Conclusion: MAS appears to be an underrecognized and potentially severe complication of VEXAS syndrome that may occur in the absence of an identifiable infectious or malignant trigger. Diagnostic overlap between both conditions may delay recognition. MAS should be suspected in VEXAS patients presenting with acute cytopenias, marked hyperferritinaemia, and organ involvement. Early use of the H-score, bone marrow examination, and prompt immunosuppressive treatment are essential to improve outcomes.
References
- Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al Somatic Mutations in UBA and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med. 2020;383(27):2628-2638. doi: 10.1056/NEJMoa2026834.
- Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E, et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol. 2022;186(3):564-574. doi: 10.1111/bjd.20805.
- Singh A, Chaudhary R. VEXAS syndrome: A newly identified X-Linked hematoinflammatory disorder - A comprehensive overview of its genetic, molecular, inflammatory, and clinical landscape. J Autoimmun. 2025;154:103425. doi: 10.1016/j.jaut.2025.103425.
- Archambeaud A, Le Dreau C, Bigot A, Kosmider O, Taleb A, Boucher L, et al. Trismus as a new feature of VEXAS syndrome. Rheumatology (Oxford). 2024;63(9):e258-e260. doi: 10.1093/rheumatology/keae135.
- de Valence B, Delaune M, Nguyen Y, Jachiet V, Heiblig M, Jean A, et al. Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry. Ann Rheum Dis. 2024;83(3):372-381. doi: 10.1136/ard-2023-224819.
- Staels F, Betrains A, Woei-A-Jin FJSH, Boeckx N, Beckers M, Bervoets A, et al. Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome. Front Immunol. 2021;12:678927. doi: 10.3389/fimmu.2021.678927. Erratum in: Front Immunol. 2021;12:748756. doi: 10.3389/fimmu.2021.748756.
